Published in J Biol Chem on October 02, 2001
The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J (2004) 4.85
The many roles of FAS receptor signaling in the immune system. Immunity (2009) 4.67
Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol (2013) 3.55
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J (2002) 2.91
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
Caspases: pharmacological manipulation of cell death. J Clin Invest (2005) 2.10
Interdimer processing mechanism of procaspase-8 activation. EMBO J (2003) 2.03
Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol (2006) 1.88
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A (2005) 1.69
A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell (2012) 1.64
Caspases and cancer. Cell Death Differ (2011) 1.56
Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Crit Care (2004) 1.49
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol (2013) 1.47
Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol Cell Biol (2004) 1.46
Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res (2007) 1.23
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat (2008) 1.22
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol (2003) 1.18
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med (2004) 1.12
Programmed cell death of dendritic cells in immune regulation. Immunol Rev (2010) 1.10
Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther (2010) 1.10
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
Fas stimulation of T lymphocytes promotes rapid intercellular exchange of death signals via membrane nanotubes. Cell Res (2009) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One (2011) 1.05
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ (2013) 1.04
Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim Biophys Acta (2011) 1.04
Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 1.03
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res (2009) 1.00
Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol (2008) 0.98
Activation and specificity of human caspase-10. Biochemistry (2010) 0.98
Disorders of apoptosis: mechanisms for autoimmunity in primary immunodeficiency diseases. J Clin Immunol (2008) 0.97
Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat Anticancer Drug Discov (2011) 0.97
The "fuzzy logic" of the death-inducing signaling complex in lymphocytes. J Clin Immunol (2003) 0.96
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res (2011) 0.95
HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol (2010) 0.95
Cellular FLIP can substitute for the herpes simplex virus type 1 latency-associated transcript gene to support a wild-type virus reactivation phenotype in mice. J Neurovirol (2008) 0.93
Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia (2005) 0.92
TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One (2011) 0.92
Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells. J Virol (2003) 0.92
Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol (2005) 0.92
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia (2004) 0.92
Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis (2012) 0.90
CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 0.90
The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway. Breast Cancer Res Treat (2010) 0.89
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem (2009) 0.88
High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem (2011) 0.88
Caspase-10-mediated heat shock protein 90 beta cleavage promotes UVB irradiation-induced cell apoptosis. Mol Cell Biol (2009) 0.88
Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly. Nat Commun (2014) 0.87
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer (2011) 0.87
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86
Apoptotic death of cancer stem cells for cancer therapy. Int J Mol Sci (2014) 0.86
Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol (2006) 0.86
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol (2002) 0.86
Regulating apoptosis in mammalian cell cultures. Cytotechnology (2006) 0.85
Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk. PLoS One (2010) 0.85
Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10. Br J Cancer (2014) 0.84
Rotational positioning of nucleosomes facilitates selective binding of p53 to response elements associated with cell cycle arrest. Nucleic Acids Res (2013) 0.84
FADD adaptor in cancer. Med Immunol (2005) 0.84
Death-effector domain-containing protein DEDD is an inhibitor of mitotic Cdk1/cyclin B1. Proc Natl Acad Sci U S A (2007) 0.84
Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. BMC Immunol (2007) 0.84
Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death Dis (2011) 0.83
AIP1: a new player in TNF signaling. J Clin Invest (2003) 0.83
Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate (2008) 0.82
Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. Oncotarget (2016) 0.81
The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J (2017) 0.81
Evidence of complex formation between FADD and c-FLIP death effector domains for the death inducing signaling complex. BMB Rep (2014) 0.81
TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression. Cell Stress Chaperones (2006) 0.80
Molecular architecture of the DED chains at the DISC: regulation of procaspase-8 activation by short DED proteins c-FLIP and procaspase-8 prodomain. Cell Death Differ (2015) 0.80
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. Cell Res (2016) 0.79
Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer. Int J Colorectal Dis (2011) 0.78
Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia. PLoS One (2014) 0.78
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. ISRN Oncol (2012) 0.77
Helicobacter pylori sensitizes TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIP. Cell Death Dis (2014) 0.77
TRPC6 channel activation promotes neonatal glomerular mesangial cell apoptosis via calcineurin/NFAT and FasL/Fas signaling pathways. Sci Rep (2016) 0.77
Human initiator caspases trigger apoptotic and autophagic phenotypes in Saccharomyces cerevisiae. Biochim Biophys Acta (2009) 0.77
DED or alive: assembly and regulation of the death effector domain complexes. Cell Death Dis (2015) 0.77
Is caspase-8 a neuroendocrine lung tumor suppressor? Cancer Biol Ther (2002) 0.77
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem (2009) 0.77
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death Differ (2017) 0.76
Xenobiotic and Endobiotic Mediated Interactions Between the Cytochrome P450 System and the Inflammatory Response in the Liver. Adv Pharmacol (2015) 0.76
Caspase-10 is the key initiator caspase involved in tributyltin-mediated apoptosis in human immune cells. J Toxicol (2012) 0.76
Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis. Stem Cells Dev (2013) 0.76
The role of apoptosis in the pathology of pancreatic cancer. Cancers (Basel) (2010) 0.75
Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer. BMC Cancer (2008) 0.75
TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 release. Neoplasia (2003) 0.75
Repurposing L-Menthol for Systems Medicine and Cancer Therapeutics? L-Menthol Induces Apoptosis through Caspase 10 and by Suppressing HSP90. OMICS (2016) 0.75
Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma. Br J Cancer (2015) 0.75
Arsenic-induced instrumental genes of apoptotic signal amplification in death-survival interplay. Cell Death Discov (2016) 0.75
IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer (2016) 0.75
The role of death-associated protein 3 in apoptosis, anoikis and human cancer. Cancer Cell Int (2015) 0.75
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer (2017) 0.75
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 8.51
Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol (1992) 7.72
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell (1992) 5.77
Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell (1999) 5.42
Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol (1994) 5.13
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature (1994) 4.67
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A (2001) 4.62
A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol (1996) 4.61
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature (1992) 4.12
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst (1989) 3.48
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest (1975) 3.39
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol (1997) 3.18
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Alterations of the PPP2R1B gene in human lung and colon cancer. Science (1998) 3.14
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol (1998) 3.11
Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (1995) 3.07
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci U S A (1988) 2.91
Biochemical purification of a mammalian slit protein as a positive regulator of sensory axon elongation and branching. Cell (1999) 2.80
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol (1984) 2.76
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Regulation of methionine synthesis in Salmonella typhimurium: mutants resistant to inhibition by analogues of methionine. Genetics (1968) 2.62
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol (2000) 2.47
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron (1999) 2.41
The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell (1996) 2.39
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
Evidence for two catalytically active kinase domains in pp90rsk. Mol Cell Biol (1996) 2.32
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Curr Biol (1999) 2.29
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ (2001) 2.27
The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell (1996) 2.26
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol (1993) 2.15
Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci U S A (1993) 2.12
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med (1985) 2.12
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol (1995) 2.09
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene (2006) 2.07
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol (1998) 2.01
Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem (1992) 1.94
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun (1986) 1.90
Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol (2001) 1.89
Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cell Biol (1997) 1.88
Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88
Identification of Xenopus S6 protein kinase homologs (pp90rsk) in somatic cells: phosphorylation and activation during initiation of cell proliferation. Mol Cell Biol (1990) 1.87
Structural and functional analysis of pp70S6k. Proc Natl Acad Sci U S A (1995) 1.84
Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene (1999) 1.82
Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer (1985) 1.77
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol (1999) 1.73
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer (1993) 1.72
Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (1995) 1.69
Characteristics of cell lines established from human colorectal carcinoma. Cancer Res (1987) 1.69
Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett (1999) 1.68
Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J Biol Chem (2000) 1.68
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res (1997) 1.66
Dissociation of pp70 ribosomal protein S6 kinase from insulin-stimulated glucose transport in 3T3-L1 adipocytes. J Biol Chem (1993) 1.64
Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene (1997) 1.64
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ (1999) 1.62
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet (1982) 1.61
Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1. Mol Cell Biol (2001) 1.61
Mitogen-activated Swiss mouse 3T3 RSK kinases I and II are related to pp44mpk from sea star oocytes and participate in the regulation of pp90rsk activity. Proc Natl Acad Sci U S A (1991) 1.61